Sevabertinib approved to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved sevabertinib (Hyrnuo) to treat adults with advanced non-small cell lung cancer (NSCLC) with HER2 mutations, that has spread to other parts of the body or cannot be removed by surgery. Sevabertinib is indicated for patients whose cancer has progressed following prior treatment and whose tumours have specific changes in the […]